Literature DB >> 15777929

Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing.

Christine E Brown1, Christine L Wright, Araceli Naranjo, Reena P Vishwanath, Wen-Chung Chang, Simon Olivares, Jamie R Wagner, Laura Bruins, Andrew Raubitschek, Laurence J N Cooper, Michael C Jensen.   

Abstract

We have developed a highly sensitive biophotonic luciferase assay as an alternative to (51)Cr-release for assessment of cell-mediated cytotoxicity. The luciferin/ATP-dependent luminescent signal of target cells stably or transiently transfected with a firefly luciferase reporter gene (fLuc:Zeo) linearly correlates with viable target cell number. Upon incubation of fLuc:Zeo(+) target cells with CD8(+) CTLs, a rapid decrease in bioluminescence was detected that correlated with antigen-specific target cell lysis. The levels of specific lysis measured by (51)Cr-release assays correlated with the attenuation in biophotonic target cell signal, thus validating this approach as a sensitive and accurate method for the measurement of cytolysis. We show that this luminescent-based cytolytic assay (LCA) is amenable for high-throughput screening of effector cell cytolytic activity, allows for the rate of cytolysis to be measured in a single micro-plate, and permits the multiplexing of cytolytic killing with other lymphocyte functional assays such as cytokine release. Importantly, this method accurately measures the cytolytic killing of target cells that are either stably or transiently transfected with a fLuc reporter gene, and thus is ideal for monitoring cytolysis of both primary autologous and immortalized target cell lines. The versatility of the non-radioactive, high-throughput, biophotonic cytolytic assay should make this method an attractive alternative to chromium-release for quantifying effector cell cytolytic activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15777929     DOI: 10.1016/j.jim.2004.11.021

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  32 in total

1.  An engineered biomarker system to monitor and modulate immune clearance of cell therapies.

Authors:  Amy Singleton; Danika Khong; Ling-Yee Chin; Shilpaa Mukundan; Matthew Li; Biju Parekkadan
Journal:  Cytotherapy       Date:  2017-09-13       Impact factor: 5.414

2.  Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells.

Authors:  C-F Hung; Y-C Tsai; L He; T-C Wu
Journal:  Gene Ther       Date:  2007-03-22       Impact factor: 5.250

3.  Mining Naïve Rabbit Antibody Repertoires by Phage Display for Monoclonal Antibodies of Therapeutic Utility.

Authors:  Haiyong Peng; Thomas Nerreter; Jing Chang; Junpeng Qi; Xiuling Li; Pabalu Karunadharma; Gustavo J Martinez; Mohammad Fallahi; Jo Soden; Jim Freeth; Roger R Beerli; Ulf Grawunder; Michael Hudecek; Christoph Rader
Journal:  J Mol Biol       Date:  2017-08-14       Impact factor: 5.469

4.  Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose- and time-dependent manner.

Authors:  J Lohmeyer; T Nerreter; J Dotterweich; H Einsele; R Seggewiss-Bernhardt
Journal:  Clin Exp Immunol       Date:  2018-05-07       Impact factor: 4.330

5.  Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy.

Authors:  Darya Alizadeh; Leying Zhang; Christine E Brown; Omar Farrukh; Michael C Jensen; Behnam Badie
Journal:  Clin Cancer Res       Date:  2010-06-22       Impact factor: 12.531

6.  PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with 89Zr-Oxine.

Authors:  Michael R Weist; Renate Starr; Brenda Aguilar; Junie Chea; Joshua K Miles; Erasmus Poku; Ethan Gerdts; Xin Yang; Saul J Priceman; Stephen J Forman; David Colcher; Christine E Brown; John E Shively
Journal:  J Nucl Med       Date:  2018-05-04       Impact factor: 10.057

7.  Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells.

Authors:  Christine E Brown; Renate Starr; Catalina Martinez; Brenda Aguilar; Massimo D'Apuzzo; Ivan Todorov; Chu-Chih Shih; Behnam Badie; Michael Hudecek; Stanley R Riddell; Michael C Jensen
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

8.  Serial diffusion MRI to monitor and model treatment response of the targeted nanotherapy CRLX101.

Authors:  Thomas S C Ng; David Wert; Hargun Sohi; Daniel Procissi; David Colcher; Andrew A Raubitschek; Russell E Jacobs
Journal:  Clin Cancer Res       Date:  2013-03-26       Impact factor: 12.531

9.  Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors.

Authors:  R Monjezi; C Miskey; T Gogishvili; M Schleef; M Schmeer; H Einsele; Z Ivics; M Hudecek
Journal:  Leukemia       Date:  2016-06-24       Impact factor: 11.528

10.  Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D.

Authors:  Mathias Krockenberger; Yvonne Dombrowski; Claudia Weidler; Monika Ossadnik; Arnd Hönig; Sebastian Häusler; Heike Voigt; Jürgen C Becker; Lin Leng; Alexander Steinle; Michael Weller; Richard Bucala; Johannes Dietl; Jörg Wischhusen
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.